Contact us if you would like more information about IntegraGen and our efforts.
09 January 2019 IntegraGen announced today its unaudited annual sales revenue for 2018. 12 November 2018 IntegraGen has announced it is collaborating with Google Cloud for the implementation of IntegraGen’s advanced genomic analysis tools, SIRIUS™ and MERCURY™ into the Google Cloud Platform. This partnership will enable widespread online availability, rapid data transfer and enhanced data security to clinicians and researchers utilizing these analytical tools. 21 October 2018 Analysis of PETACC-8 clinical trial samples demonstrates company’s proprietary miR-31 microRNA biomarkers identifies subpopulations of patients with resected stage III colon cancer who benefit from the addition of cetuximab to FOLFOX adjuvant therapy IntegraGen announced today that it presented data on the company’s proprietary miR-31 (…) » 20 September 2018 IntegraGen has announced today its financial results for the first half of semester 2018 with the accounts having been examined by the company’s Board of Directors on September 20, 2018. 19 September 2018 IntegraGen has been nominated for a 2018 PrixGalien MedStartup Award, a joint initiative between The Galien Foundation and Business France to encourage and reward international partnerships between French and North American innovators in the Life Sciences Industry. IntegraGen was selected as a nominee by an (…) » 06 September 2018 GoPath Laboratories, IntegraGen’s North American licensing partner for the company’s miR-31-3p test, announced that the American Medical Association (AMA) has assigned a new, discreet CPT (Current Procedural Technology) code to facilitate reimbursement of miR-31now®, a proprietary miRNA-based molecular test which predicts the potential clinical benefits associated with (…) » 04 September 2018 IntegraGen announces the publication of the results of a definitive study reporting on the analysis of the expression of miR-31-3p in tumors from 370 RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial (AIO KRK-0306). The paper, entitled “Validation of miR-31-3p Expression Level to Predict (…) » 31 July 2018 IntegraGen has announced that it has been selected by the Sequencing Omics Information Analysis (SeqOIA) Cooperative Health Group (GCS) for the operation of its high throughput sequencing platform. The SeqOIA GCS, which includes the Assistance Publique- Hôpitaux de Paris, the Institut Curie and the Gustave Roussy Cancer Center, (…) » 09 July 2018 IntegraGen today announced the company’s sales revenue for the first half of 2018. IntegraGen’s revenue amounted to € 3.6 million as of June 30, 2018, up 17% from 2017. 01 June 2018 GoPath Laboratories, IntegraGen’s licensing partner in the U.S., has announced that it will launch a propriety new test, miR-31now™ during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago. The miR-31now test is the first positive theranostic test for patients with (…) » IntegraGen Reports Revenue of €6.9 million for 2018 (+11%) and Cash Position of €4.0 million
IntegraGen Announces Collaboration with Google Cloud to Offer Large Scale Genomic Analysis Tools for Clinicians and Medical Researchers
IntegraGen presents new data expanding application of miR-31 to stage III colon cancer during ESMO 2018
IntegraGen Reports Financial Results for 1st Half of 2018
IntegraGen nominated for a 2018 PrixGalien MedStartup Award
IntegraGen’s licensing partner GoPath Labs announces new CPT Code for reimbursement of miR-31-3p test in the U.S.
IntegraGen Announces Publication of miR-31-3p Data in Clinical Cancer Research
The SeqOIA Cooperative Health Group selects IntegraGen as the operator of its sequencing platform as part of the France Genomic Medicine 2025 Plan
IntegraGen Reports 17% Revenue Growth During First Half of 2018
GoPath Labs Announces North American Launch of miR-31-3p expression test
